佰仁医疗董事长金磊：以全球化视角 原研创新布局结构性心脏病领域植介入器械全产品线

Core Insights - Beijing Bairen Medical Technology Co., Ltd. has established itself as an innovative leader in the structural heart disease sector with 22 Class III medical device registrations and a global presence [1][5] - The company's chairman, Jin Lei, emphasized that international expansion is not optional but a necessity for the business [5][6] - Bairen Medical is focused on developing high-end medical devices for animal-derived implant interventions, breaking the monopoly of foreign companies in the domestic market [5][6] Company Strategy - The company has adopted a dual strategy of "technological differentiation + industrialization of product registration rules" to drive its international expansion [1][5] - In April 2023, Bairen Medical fully acquired Tianqiong Innovation, a company specializing in polymer implant materials, and established a research center for these materials [5][6] - The company plans to apply for FDA 510K registration for four products and is also working on registering seven existing domestic biological patches for the overseas market [5][6] Market Position - Bairen Medical is the only listed leader in the domestic structural heart disease field and has successfully expanded into overseas markets [5][6] - The company has over ten products currently applying for registration in Indonesia, aiming not only to sell products but also to educate local practitioners [6][7] Epidemiological Insights - There is a significant epidemiological difference between heart valve disease patients in China and those in Europe and the U.S., which influences the importance of original product development [7][8] Financial Performance - In Q1 2025, Bairen Medical reported a revenue of 100 million yuan, a year-on-year increase of 31.3%, and a net profit of approximately 32.5 million yuan, up 290.69% [9] - The company invests over 20% of its revenue into R&D, with R&D expenses projected to reach 151 million yuan in 2024, a 53.26% increase [9] Future Directions - Bairen Medical is focusing on two core development directions: AI-driven modular valve intervention and breakthroughs in tissue treatment technology [11][12] - The company aims to leverage technological innovation to enhance treatment options and contribute to the national strategy for technological advancement [12]